Global Botulism Illness Market

Botulism Illness Comprehensive Study by Type (Antibiotics, Antitoxins, Other), Application (Hospitals, Clinics, Other), Distribution Channel (OTC, Prescribed) Players and Region - Global Market Outlook to 2027

Botulism Illness Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Botulism Illness Market Overview:
Botulism is a rare but serious fatal paralytic disorder, caused by neurotoxins produced by a bacteria Clostridium botulinum. Rapid advancement in the are of medical technologies and government initiatives supporting research and development in the healthcare industry and the availability of favourable reimbursement policies are the major driving agent in the growth of the very market. In addition, owing to strong efforts by WHO and CDC, the disease is getting irradiated slowly.

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Historical Period2017-2021
UnitValue (USD Million)
Key Companies ProfiledMicrobiotix (United States), XOMA Corporation (United States), Allergan Inc (Ireland), Pfizer Inc. (United States), Molecular Targeting Technologies (United States), AlphaVax (United States), Morphotek (United States), Azidus (India) and Canbex therapeutics ltd
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Growth Drivers
  • Availability of Proper Treatment of Botulism Illness
  • Huge Spending on R&D Activities and Clean Environment Worldwide

Roadblocks
  • Lack of Awareness in Some Undeveloped Nations
  • Unavailability of Proper Healthcare Infrastructure

Opportunities
  • Rising Awareness About the Care and Treatment in Developing Economies

Challenges
  • High Capital Investments for Treatments and Late Diagnosis of the Disease
  • Unaffordability in Middle-Income Countries


Competitive Landscape:

Some of the key players profiled in the report are Microbiotix (United States), XOMA Corporation (United States), Allergan Inc (Ireland), Pfizer Inc. (United States), Molecular Targeting Technologies (United States), AlphaVax (United States), Morphotek (United States), Azidus (India) and Canbex therapeutics ltd. Analyst at AMA Research see United States Players to retain maximum share of Global Botulism Illness market by 2027. Considering Market by Distribution Channel, the sub-segment i.e. OTC will boost the Botulism Illness market.

What Can be Explored with the Botulism Illness Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Botulism Illness Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Botulism Illness
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Botulism Illness market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Botulism Illness market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Medicines Manufacturers, Medicine Suppliers/Distributors, End User and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Antibiotics
  • Antitoxins
  • Other
By Application
  • Hospitals
  • Clinics
  • Other
By Distribution Channel
  • OTC
  • Prescribed

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Availability of Proper Treatment of Botulism Illness
      • 3.2.2. Huge Spending on R&D Activities and Clean Environment Worldwide
    • 3.3. Market Challenges
      • 3.3.1. High Capital Investments for Treatments and Late Diagnosis of the Disease
      • 3.3.2. Unaffordability in Middle-Income Countries
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Botulism Illness, by Type, Application, Distribution Channel and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Botulism Illness (Value)
      • 5.2.1. Global Botulism Illness by: Type (Value)
        • 5.2.1.1. Antibiotics
        • 5.2.1.2. Antitoxins
        • 5.2.1.3. Other
      • 5.2.2. Global Botulism Illness by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Other
      • 5.2.3. Global Botulism Illness by: Distribution Channel (Value)
        • 5.2.3.1. OTC
        • 5.2.3.2. Prescribed
      • 5.2.4. Global Botulism Illness Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Botulism Illness: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Microbiotix (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. XOMA Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Allergan Inc (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Molecular Targeting Technologies (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AlphaVax (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Morphotek (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Azidus (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Canbex therapeutics ltd
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Botulism Illness Sale, by Type, Application, Distribution Channel and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Botulism Illness (Value)
      • 7.2.1. Global Botulism Illness by: Type (Value)
        • 7.2.1.1. Antibiotics
        • 7.2.1.2. Antitoxins
        • 7.2.1.3. Other
      • 7.2.2. Global Botulism Illness by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Other
      • 7.2.3. Global Botulism Illness by: Distribution Channel (Value)
        • 7.2.3.1. OTC
        • 7.2.3.2. Prescribed
      • 7.2.4. Global Botulism Illness Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Botulism Illness: by Type(USD Million)
  • Table 2. Botulism Illness Antibiotics , by Region USD Million (2016-2021)
  • Table 3. Botulism Illness Antitoxins , by Region USD Million (2016-2021)
  • Table 4. Botulism Illness Other , by Region USD Million (2016-2021)
  • Table 5. Botulism Illness: by Application(USD Million)
  • Table 6. Botulism Illness Hospitals , by Region USD Million (2016-2021)
  • Table 7. Botulism Illness Clinics , by Region USD Million (2016-2021)
  • Table 8. Botulism Illness Other , by Region USD Million (2016-2021)
  • Table 9. Botulism Illness: by Distribution Channel(USD Million)
  • Table 10. Botulism Illness OTC , by Region USD Million (2016-2021)
  • Table 11. Botulism Illness Prescribed , by Region USD Million (2016-2021)
  • Table 12. South America Botulism Illness, by Country USD Million (2016-2021)
  • Table 13. South America Botulism Illness, by Type USD Million (2016-2021)
  • Table 14. South America Botulism Illness, by Application USD Million (2016-2021)
  • Table 15. South America Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 16. Brazil Botulism Illness, by Type USD Million (2016-2021)
  • Table 17. Brazil Botulism Illness, by Application USD Million (2016-2021)
  • Table 18. Brazil Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 19. Argentina Botulism Illness, by Type USD Million (2016-2021)
  • Table 20. Argentina Botulism Illness, by Application USD Million (2016-2021)
  • Table 21. Argentina Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 22. Rest of South America Botulism Illness, by Type USD Million (2016-2021)
  • Table 23. Rest of South America Botulism Illness, by Application USD Million (2016-2021)
  • Table 24. Rest of South America Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 25. Asia Pacific Botulism Illness, by Country USD Million (2016-2021)
  • Table 26. Asia Pacific Botulism Illness, by Type USD Million (2016-2021)
  • Table 27. Asia Pacific Botulism Illness, by Application USD Million (2016-2021)
  • Table 28. Asia Pacific Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 29. China Botulism Illness, by Type USD Million (2016-2021)
  • Table 30. China Botulism Illness, by Application USD Million (2016-2021)
  • Table 31. China Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 32. Japan Botulism Illness, by Type USD Million (2016-2021)
  • Table 33. Japan Botulism Illness, by Application USD Million (2016-2021)
  • Table 34. Japan Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 35. India Botulism Illness, by Type USD Million (2016-2021)
  • Table 36. India Botulism Illness, by Application USD Million (2016-2021)
  • Table 37. India Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 38. South Korea Botulism Illness, by Type USD Million (2016-2021)
  • Table 39. South Korea Botulism Illness, by Application USD Million (2016-2021)
  • Table 40. South Korea Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 41. Taiwan Botulism Illness, by Type USD Million (2016-2021)
  • Table 42. Taiwan Botulism Illness, by Application USD Million (2016-2021)
  • Table 43. Taiwan Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 44. Australia Botulism Illness, by Type USD Million (2016-2021)
  • Table 45. Australia Botulism Illness, by Application USD Million (2016-2021)
  • Table 46. Australia Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 47. Rest of Asia-Pacific Botulism Illness, by Type USD Million (2016-2021)
  • Table 48. Rest of Asia-Pacific Botulism Illness, by Application USD Million (2016-2021)
  • Table 49. Rest of Asia-Pacific Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 50. Europe Botulism Illness, by Country USD Million (2016-2021)
  • Table 51. Europe Botulism Illness, by Type USD Million (2016-2021)
  • Table 52. Europe Botulism Illness, by Application USD Million (2016-2021)
  • Table 53. Europe Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 54. Germany Botulism Illness, by Type USD Million (2016-2021)
  • Table 55. Germany Botulism Illness, by Application USD Million (2016-2021)
  • Table 56. Germany Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 57. France Botulism Illness, by Type USD Million (2016-2021)
  • Table 58. France Botulism Illness, by Application USD Million (2016-2021)
  • Table 59. France Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 60. Italy Botulism Illness, by Type USD Million (2016-2021)
  • Table 61. Italy Botulism Illness, by Application USD Million (2016-2021)
  • Table 62. Italy Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 63. United Kingdom Botulism Illness, by Type USD Million (2016-2021)
  • Table 64. United Kingdom Botulism Illness, by Application USD Million (2016-2021)
  • Table 65. United Kingdom Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 66. Netherlands Botulism Illness, by Type USD Million (2016-2021)
  • Table 67. Netherlands Botulism Illness, by Application USD Million (2016-2021)
  • Table 68. Netherlands Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 69. Rest of Europe Botulism Illness, by Type USD Million (2016-2021)
  • Table 70. Rest of Europe Botulism Illness, by Application USD Million (2016-2021)
  • Table 71. Rest of Europe Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 72. MEA Botulism Illness, by Country USD Million (2016-2021)
  • Table 73. MEA Botulism Illness, by Type USD Million (2016-2021)
  • Table 74. MEA Botulism Illness, by Application USD Million (2016-2021)
  • Table 75. MEA Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 76. Middle East Botulism Illness, by Type USD Million (2016-2021)
  • Table 77. Middle East Botulism Illness, by Application USD Million (2016-2021)
  • Table 78. Middle East Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 79. Africa Botulism Illness, by Type USD Million (2016-2021)
  • Table 80. Africa Botulism Illness, by Application USD Million (2016-2021)
  • Table 81. Africa Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 82. North America Botulism Illness, by Country USD Million (2016-2021)
  • Table 83. North America Botulism Illness, by Type USD Million (2016-2021)
  • Table 84. North America Botulism Illness, by Application USD Million (2016-2021)
  • Table 85. North America Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 86. United States Botulism Illness, by Type USD Million (2016-2021)
  • Table 87. United States Botulism Illness, by Application USD Million (2016-2021)
  • Table 88. United States Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 89. Canada Botulism Illness, by Type USD Million (2016-2021)
  • Table 90. Canada Botulism Illness, by Application USD Million (2016-2021)
  • Table 91. Canada Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 92. Mexico Botulism Illness, by Type USD Million (2016-2021)
  • Table 93. Mexico Botulism Illness, by Application USD Million (2016-2021)
  • Table 94. Mexico Botulism Illness, by Distribution Channel USD Million (2016-2021)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Botulism Illness: by Type(USD Million)
  • Table 105. Botulism Illness Antibiotics , by Region USD Million (2022-2027)
  • Table 106. Botulism Illness Antitoxins , by Region USD Million (2022-2027)
  • Table 107. Botulism Illness Other , by Region USD Million (2022-2027)
  • Table 108. Botulism Illness: by Application(USD Million)
  • Table 109. Botulism Illness Hospitals , by Region USD Million (2022-2027)
  • Table 110. Botulism Illness Clinics , by Region USD Million (2022-2027)
  • Table 111. Botulism Illness Other , by Region USD Million (2022-2027)
  • Table 112. Botulism Illness: by Distribution Channel(USD Million)
  • Table 113. Botulism Illness OTC , by Region USD Million (2022-2027)
  • Table 114. Botulism Illness Prescribed , by Region USD Million (2022-2027)
  • Table 115. South America Botulism Illness, by Country USD Million (2022-2027)
  • Table 116. South America Botulism Illness, by Type USD Million (2022-2027)
  • Table 117. South America Botulism Illness, by Application USD Million (2022-2027)
  • Table 118. South America Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 119. Brazil Botulism Illness, by Type USD Million (2022-2027)
  • Table 120. Brazil Botulism Illness, by Application USD Million (2022-2027)
  • Table 121. Brazil Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 122. Argentina Botulism Illness, by Type USD Million (2022-2027)
  • Table 123. Argentina Botulism Illness, by Application USD Million (2022-2027)
  • Table 124. Argentina Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 125. Rest of South America Botulism Illness, by Type USD Million (2022-2027)
  • Table 126. Rest of South America Botulism Illness, by Application USD Million (2022-2027)
  • Table 127. Rest of South America Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 128. Asia Pacific Botulism Illness, by Country USD Million (2022-2027)
  • Table 129. Asia Pacific Botulism Illness, by Type USD Million (2022-2027)
  • Table 130. Asia Pacific Botulism Illness, by Application USD Million (2022-2027)
  • Table 131. Asia Pacific Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 132. China Botulism Illness, by Type USD Million (2022-2027)
  • Table 133. China Botulism Illness, by Application USD Million (2022-2027)
  • Table 134. China Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 135. Japan Botulism Illness, by Type USD Million (2022-2027)
  • Table 136. Japan Botulism Illness, by Application USD Million (2022-2027)
  • Table 137. Japan Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 138. India Botulism Illness, by Type USD Million (2022-2027)
  • Table 139. India Botulism Illness, by Application USD Million (2022-2027)
  • Table 140. India Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 141. South Korea Botulism Illness, by Type USD Million (2022-2027)
  • Table 142. South Korea Botulism Illness, by Application USD Million (2022-2027)
  • Table 143. South Korea Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 144. Taiwan Botulism Illness, by Type USD Million (2022-2027)
  • Table 145. Taiwan Botulism Illness, by Application USD Million (2022-2027)
  • Table 146. Taiwan Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 147. Australia Botulism Illness, by Type USD Million (2022-2027)
  • Table 148. Australia Botulism Illness, by Application USD Million (2022-2027)
  • Table 149. Australia Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 150. Rest of Asia-Pacific Botulism Illness, by Type USD Million (2022-2027)
  • Table 151. Rest of Asia-Pacific Botulism Illness, by Application USD Million (2022-2027)
  • Table 152. Rest of Asia-Pacific Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 153. Europe Botulism Illness, by Country USD Million (2022-2027)
  • Table 154. Europe Botulism Illness, by Type USD Million (2022-2027)
  • Table 155. Europe Botulism Illness, by Application USD Million (2022-2027)
  • Table 156. Europe Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 157. Germany Botulism Illness, by Type USD Million (2022-2027)
  • Table 158. Germany Botulism Illness, by Application USD Million (2022-2027)
  • Table 159. Germany Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 160. France Botulism Illness, by Type USD Million (2022-2027)
  • Table 161. France Botulism Illness, by Application USD Million (2022-2027)
  • Table 162. France Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 163. Italy Botulism Illness, by Type USD Million (2022-2027)
  • Table 164. Italy Botulism Illness, by Application USD Million (2022-2027)
  • Table 165. Italy Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 166. United Kingdom Botulism Illness, by Type USD Million (2022-2027)
  • Table 167. United Kingdom Botulism Illness, by Application USD Million (2022-2027)
  • Table 168. United Kingdom Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 169. Netherlands Botulism Illness, by Type USD Million (2022-2027)
  • Table 170. Netherlands Botulism Illness, by Application USD Million (2022-2027)
  • Table 171. Netherlands Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 172. Rest of Europe Botulism Illness, by Type USD Million (2022-2027)
  • Table 173. Rest of Europe Botulism Illness, by Application USD Million (2022-2027)
  • Table 174. Rest of Europe Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 175. MEA Botulism Illness, by Country USD Million (2022-2027)
  • Table 176. MEA Botulism Illness, by Type USD Million (2022-2027)
  • Table 177. MEA Botulism Illness, by Application USD Million (2022-2027)
  • Table 178. MEA Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 179. Middle East Botulism Illness, by Type USD Million (2022-2027)
  • Table 180. Middle East Botulism Illness, by Application USD Million (2022-2027)
  • Table 181. Middle East Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 182. Africa Botulism Illness, by Type USD Million (2022-2027)
  • Table 183. Africa Botulism Illness, by Application USD Million (2022-2027)
  • Table 184. Africa Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 185. North America Botulism Illness, by Country USD Million (2022-2027)
  • Table 186. North America Botulism Illness, by Type USD Million (2022-2027)
  • Table 187. North America Botulism Illness, by Application USD Million (2022-2027)
  • Table 188. North America Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 189. United States Botulism Illness, by Type USD Million (2022-2027)
  • Table 190. United States Botulism Illness, by Application USD Million (2022-2027)
  • Table 191. United States Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 192. Canada Botulism Illness, by Type USD Million (2022-2027)
  • Table 193. Canada Botulism Illness, by Application USD Million (2022-2027)
  • Table 194. Canada Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 195. Mexico Botulism Illness, by Type USD Million (2022-2027)
  • Table 196. Mexico Botulism Illness, by Application USD Million (2022-2027)
  • Table 197. Mexico Botulism Illness, by Distribution Channel USD Million (2022-2027)
  • Table 198. Research Programs/Design for This Report
  • Table 199. Key Data Information from Secondary Sources
  • Table 200. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Botulism Illness: by Type USD Million (2016-2021)
  • Figure 5. Global Botulism Illness: by Application USD Million (2016-2021)
  • Figure 6. Global Botulism Illness: by Distribution Channel USD Million (2016-2021)
  • Figure 7. South America Botulism Illness Share (%), by Country
  • Figure 8. Asia Pacific Botulism Illness Share (%), by Country
  • Figure 9. Europe Botulism Illness Share (%), by Country
  • Figure 10. MEA Botulism Illness Share (%), by Country
  • Figure 11. North America Botulism Illness Share (%), by Country
  • Figure 12. Global Botulism Illness share by Players 2021 (%)
  • Figure 13. Global Botulism Illness share by Players (Top 3) 2021(%)
  • Figure 14. Global Botulism Illness share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Microbiotix (United States) Revenue, Net Income and Gross profit
  • Figure 17. Microbiotix (United States) Revenue: by Geography 2021
  • Figure 18. XOMA Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 19. XOMA Corporation (United States) Revenue: by Geography 2021
  • Figure 20. Allergan Inc (Ireland) Revenue, Net Income and Gross profit
  • Figure 21. Allergan Inc (Ireland) Revenue: by Geography 2021
  • Figure 22. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Pfizer Inc. (United States) Revenue: by Geography 2021
  • Figure 24. Molecular Targeting Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 25. Molecular Targeting Technologies (United States) Revenue: by Geography 2021
  • Figure 26. AlphaVax (United States) Revenue, Net Income and Gross profit
  • Figure 27. AlphaVax (United States) Revenue: by Geography 2021
  • Figure 28. Morphotek (United States) Revenue, Net Income and Gross profit
  • Figure 29. Morphotek (United States) Revenue: by Geography 2021
  • Figure 30. Azidus (India) Revenue, Net Income and Gross profit
  • Figure 31. Azidus (India) Revenue: by Geography 2021
  • Figure 32. Canbex therapeutics ltd Revenue, Net Income and Gross profit
  • Figure 33. Canbex therapeutics ltd Revenue: by Geography 2021
  • Figure 34. Global Botulism Illness: by Type USD Million (2022-2027)
  • Figure 35. Global Botulism Illness: by Application USD Million (2022-2027)
  • Figure 36. Global Botulism Illness: by Distribution Channel USD Million (2022-2027)
  • Figure 37. South America Botulism Illness Share (%), by Country
  • Figure 38. Asia Pacific Botulism Illness Share (%), by Country
  • Figure 39. Europe Botulism Illness Share (%), by Country
  • Figure 40. MEA Botulism Illness Share (%), by Country
  • Figure 41. North America Botulism Illness Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Microbiotix (United States)
  • XOMA Corporation (United States)
  • Allergan Inc (Ireland)
  • Pfizer Inc. (United States)
  • Molecular Targeting Technologies (United States)
  • AlphaVax (United States)
  • Morphotek (United States)
  • Azidus (India)
  • Canbex therapeutics ltd
Select User Access Type

Key Highlights of Report


May 2022 233 Pages 77 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Botulism Illness Market Quantitative research analysis
Global Botulism Illness Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Botulism Illness market are Microbiotix (United States), XOMA Corporation (United States), Allergan Inc (Ireland), Pfizer Inc. (United States), Molecular Targeting Technologies (United States), AlphaVax (United States), Morphotek (United States), Azidus (India) and Canbex therapeutics ltd, to name a few.

Know More About Global Botulism Illness Market Report?

Have a Query? Click Here

Other Related Reports

Drug Eluting Beads Comprehensive Study by Type (LC Beads, QuadraSpheres, Oncozene Beads), Application (Hospitals, Specialized Clinics, Ambulatory Surgical Centers, Research Centers), Drug (Doxorubici...
$ 3800
Breast Cancer Monoclonal Antibodies Comprehensive Study by Type (Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies), Application (Hospitals, Retail Pharm...
$ 3500
Sotalol Drug Comprehensive Study by Application (Ventricular Arrhythmias, Atrial Fibrillation/Flutter, Supraventricular Arrhythmias), Distribution Channel (Sales Channel Hospital Pharmacies, Drug Sto...
$ 3650
Eye Infections Treatment Comprehensive Study by Type (Gels and Creams, Eye Drops, Drug), Application (Ophthalmology Clinics, Hospitals, Others), Eye Infection (Conjunctivitis or Pink Eye, Viral Kerat...
$ 3750
Allopurinol Tablets Comprehensive Study by Type (100 mg, 300 mg), Application (Healthcare Industry, Hospitals), Distribution Channel (Hospitals, Pharma Retail, Clinics, Others), Side Effects (Nausea,...
$ 3350
Urethritis Drugs Comprehensive Study by Type (Gonococcal Urethritis, Non gonococcal Urethritis), End-users (Hospitals and Clinics, Research and Academics, Others), Drugs Treatment (Antivirals, Anti-B...
$ 3800